EUVIMEDEUVIMED entdecken
Open Access

Utility of Prognostic Staging Systems in Transthyretin Amyloidosis Cardiomyopathy in the Era of Available Disease‐Modifying Treatment

Jens K Skov iD, Tor S Clemmensen iD, Christopher G Scott iD, Omar F Abou Ezzedine iD, Ian C Chang, Angela Dispenzieri iD, Steen H Poulsen, Martha Grogan iD

Journal of the American Heart Association · 18.08.2026 · 15 (16)

DOI: 10.1161/jaha.125.048585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 18.08.2026. Verfasst von Jens K Skov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine Aarhus University and Aarhus University Hospital Aarhus N Denmark. Hauptthemen laut MEDLINE: Cardiomyopathies, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prognostic staging systems in transthyretin amyloid (ATTR) cardiomyopathy were developed before the introduction of disease‐modifying treatment. We therefore evaluated contemporary risk stratification according to different staging systems in patients with ATTR cardiomyopathy.

Methods

All patients with newly diagnosed ATTR cardiomyopathy and baseline biomarker measurements from 2019 to 2023 were included from Mayo Clinic, Rochester, MN. Prognostic outcomes were calculated with Kaplan–Meier analysis for 3e staging systems in the main analysis: the National Amyloidosis Centre (NAC) staging system; a modified Mayo staging system using hsTNT (high‐sensitivity troponin T) cutoff >65 ng/L; the extended NAC model with a fourth stage (NT‐proBNP [N‐terminal pro‐B‐type natriuretic peptide] >10 000 ng/L).

Results

The study population consisted of 441 patients with a median age of 76 years, 93% were men, 85% were initiated on tafamidis, and 94% had wild‐type ATTR. Median follow‐up was 3.4 years, and 109 deaths occurred during follow‐up. The 3‐year survival for the Mayo stages were 92.3% (88.7–95.9) for stage I, 71.6% (63.0–81.3) for stage II, and 43.5% (32.4–58.5) for stage III. For the NAC system, 3‐year survival were 92.0% (89.0–95.7), 67.5% (59.0–77.3), and 47.0% (34.7–63.5) for stages I, II, and III, respectively. The 3‐year survival by the extended NAC system was 92.0 (69.0–79.2), 69.0% (60.1–79.2), 53.2% (39.9–70.8) and 34.4% (17.4–68.0) for stages I, II, III, and IV, respectively.

Conclusions

In a contemporary cohort of patients with ATTR cardiomyopathy, the NAC and modified Mayo staging systems remained equally effective in delineating clinically meaningful prognostic groups, whereas the extended NAC system identified a stage IV subgroup with high mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomyopathiesAmyloid Neuropathies, FamilialHumansPrognosisFemaleMaleAgedBiomarkersPeptide FragmentsNatriuretic Peptide, BrainTroponin TRisk AssessmentAged, 80 and overRetrospective StudiesPredictive Value of TestsBenzoxazoles

Stichwörter der Autor:innen

amyloidosisprognosisstagingtransthyretin

Substanzen

BiomarkersPeptide FragmentsNatriuretic Peptide, BrainTroponin Tpro-brain natriuretic peptide (1-76)tafamidisBenzoxazoles

Autor:innen und Institutionen

  • Department of Clinical Medicine Aarhus University and Aarhus University Hospital Aarhus N Denmark.
  • Department of Clinical Epidemiology Aarhus University and Aarhus University Hospital Aarhus N Denmark.
  • Department of Cardiology Aarhus University Hospital Aarhus N Denmark.
  • Department of Cardiology Gødstrup Regional Hospital Herning Denmark.
  • Department of Quantitative Health Science and Biostatistics Mayo Clinic Rochester MN USA.
  • Department of Cardiovascular Diseases Mayo Clinic Rochester MN USA.

ORCID-Profile: Jens K Skov, Tor S Clemmensen, Christopher G Scott, Omar F Abou Ezzedine, Angela Dispenzieri, Martha Grogan

Zitieren

APA

Skov, J. K., Clemmensen, T. S., Scott, C. G., Abou Ezzedine, O. F., Chang, I. C., Dispenzieri, A., Poulsen, S. H., & Grogan, M. (2026). Utility of Prognostic Staging Systems in Transthyretin Amyloidosis Cardiomyopathy in the Era of Available Disease‐Modifying Treatment. Journal of the American Heart Association, 15(16). https://doi.org/10.1161/jaha.125.048585

Vancouver

Skov JK, Clemmensen TS, Scott CG, Abou Ezzedine OF, Chang IC, Dispenzieri A, et al. Utility of Prognostic Staging Systems in Transthyretin Amyloidosis Cardiomyopathy in the Era of Available Disease‐Modifying Treatment. Journal of the American Heart Association. 2026;15(16). doi:10.1161/jaha.125.048585

BibTeX
@article{Skov2026,
  author = {Skov, Jens K and Clemmensen, Tor S and Scott, Christopher G and Abou Ezzedine, Omar F and Chang, Ian C and Dispenzieri, Angela and Poulsen, Steen H and Grogan, Martha},
  title = {Utility of Prognostic Staging Systems in Transthyretin Amyloidosis Cardiomyopathy in the Era of Available Disease‐Modifying Treatment},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {16},
  doi = {10.1161/jaha.125.048585}
}
Kostenlos starten →